文献速递肝病

肌肉减少症与非酒精性脂肪性肝病患者严重肝纤维化相关

Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2016-12-27

该研究纳入225例经组织学诊断的非酒精性脂肪性肝病(NAFLD)患者,用生物电阻抗分析评估骨骼肌质量指数定义肌肉减少症。肌肉减少症患病率随纤维化严重程度线性增加,严重纤维化(F3-F4)在肌肉减少症患者中为48.3%,无肌肉减少症患者中为20.4%(P<0.001)。校正混杂因素后,肌肉减少症与严重纤维化独立相关(OR 2.36,95%CI 1.16-4.77,P=0.01)。

要点

  • 肌肉减少症患病率随NAFLD患者肝纤维化严重程度线性增加。
  • 肌肉减少症患者严重纤维化(F3-F4)比例为48.3%,无肌肉减少症患者为20.4%。
  • 校正混杂因素后,肌肉减少症与严重纤维化独立相关(OR 2.36)。

核心结论

  • 在代谢性疾病和晚期肝病高发的西方NAFLD患者中,肌肉减少症与肝纤维化和脂肪变严重程度相关,且独立于肝脏和代谢危险因素。
  • 需要研究评估减少肌肉减少症的干预措施对NAFLD进展的影响。

研究设计与样本

  • 研究纳入225例连续的组织学诊断NAFLD患者(Kleiner评分)。
  • 通过生物电阻抗分析评估骨骼肌质量指数(四肢骨骼肌总质量(kg)/体重(kg)×100)。
  • 肌肉减少症定义为男性骨骼肌质量指数≤37、女性≤28。

主要发现

  • 肌肉减少症患病率随纤维化严重程度线性增加,严重纤维化(F3-F4)在肌肉减少症患者中为48.3%,在纤维化≤F2患者中为20.4%(P<0.001)。
  • 校正混杂因素后,肌肉减少症与严重纤维化独立相关(OR 2.36,95%CI 1.16-4.77,P=0.01)。
  • 校正混杂因素后,年龄>50岁(OR 6.53,95%CI 2.95-14.4,P<0.001)、空腹血糖受损/糖尿病(OR 2.14,95%CI 1.05-4.35,P=0.03)和NASH(OR 13.3,95%CI 1.64-108.1,P=0.01)与严重纤维化相关。
  • 肌肉减少症与NASH(P=0.01)、脂肪变严重程度(P=0.006)和气球样变(P=0.01)显著相关;校正混杂因素后,仅与严重脂肪变的相关性维持(OR 2.02,95%CI 1.06-3.83,P=0.03)。

局限性

  • 需要研究评估减少肌肉减少症的干预措施对NAFLD进展的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD). AIM: To test the prevalence of sarcopenia and its relation with the severity of fibrosis (main outcome) and the entire spectrum of liver histology in patients with NAFLD. METHODS: We considered 225 consecutive patients with histological diagnosis of NAFLD (Kleiner score). The skeletal muscle index (%) (total appendicular skeletal muscle mass (kg)/weight (kg) × 100), a validated measure of sarcopenia, was assessed by bioelectrical impedance analysis. Sarcopenia was defined as a skeletal muscle mass index ≤37 in males and ≤28 in females. RESULTS: The prevalence of sarcopenia showed a linear increase with the severity of fibrosis, and severe fibrosis (F3-F4) was more than doubled in sarcopenia (48.3% vs. 20.4% in fibrosis ≤F2, P < 0.001). After adjusting for confounders, the association of sarcopenia with severe fibrosis was maintained (OR 2.36, CI 1.16-4.77, P = 0.01), together with age > 50 (OR 6.53, CI 2.95-14.4, P < 0.001), IFG/Diabetes (OR 2.14, CI 1.05-4.35, P = 0.03) and NASH (OR 13.3, CI 1.64-108.1, P = 0.01). Similarly, a significant association was found between sarcopenia and NASH (P = 0.01), steatosis severity (P = 0.006), and ballooning (P = 0.01), but only the association with severe steatosis was maintained (OR 2.02, CI 1.06-3.83, P = 0.03) after adjusting for confounders. CONCLUSIONS: In Western patients with NAFLD, with high prevalence of metabolic disorders and advanced liver disease, sarcopenia was associated with the severity of fibrosis and steatosis, independently of hepatic and metabolic risk factors. Studies are needed to assess the impact of interventions to reduce sarcopenia on NAFLD progression.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2016. PMID: 28028821. doi:10.1111/apt.13889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。